As the Biden administration begins the process of negotiating prices for 10 costly drugs on behalf of Medicare and its beneficiaries as authorized in last year’s Inflation Reduction Act, KFF Executive Vice President for Health Policy Larry Levitt probes some likely arguments against it in this op-ed column in The New York Times. The column also examines the policy and political implications of the debate and pending legal challenges.